Key Drivers
- Gross Margin
- Cash Burn
- Leverage Risk
AIAI Summary
TLX has shifted from a pure pipeline bet to an execution-driven commercialization story after multiple FDA milestones, but with negative operating/free cash flow, heavy debt service, and a legal overhang, the stock now looks priced for success before durable self-funding is proven.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Leverage Risk
TLX has decent gross profitability and liquidity, but thin net margins, negative cash flow, and elevated leverage are weighing on the investment case despite a still-premium valuation.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Breakout strength
- •Overextended rally
TLX has turned decisively bullish over the last month, breaking out to a new high while remaining extended and vulnerable to a short-term pause, with support near $11.30-$11.53 and resistance around $12.00.
Sharp rally since 2026-06-24 suggests short-term pullback or consolidation risk
Sentiment & News
Key News Insights:
- •Glioma Focus
- •FDA Alignment
- •Pipeline Progress
Telix is advancing both neuro-oncology and prostate cancer programs, with educational updates highlighting its theranostics strategy and FDA alignment de-risking the ProstACT Global Phase 3 trial.
The FDA meeting meaningfully lowers regulatory uncertainty for Telix's prostate cancer program while sustaining momentum across its broader oncology pipeline
Similar Companies in Healthcare
Other companies in the same sector with AI ratings